Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Colorcon
McKinsey
Boehringer Ingelheim
Johnson and Johnson

Last Updated: June 27, 2022

LAMICTAL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Lamictal patents expire, and when can generic versions of Lamictal launch?

Lamictal is a drug marketed by Glaxosmithkline Llc and is included in four NDAs. There are five patents protecting this drug.

The generic ingredient in LAMICTAL is lamotrigine. There are thirty-two drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lamictal

A generic version of LAMICTAL was approved as lamotrigine by DR REDDYS LABS LTD on January 22nd, 2009.

  Try it Free

Drug patent expirations by year for LAMICTAL
Drug Prices for LAMICTAL

See drug prices for LAMICTAL

Drug Sales Revenue Trends for LAMICTAL

See drug sales revenues for LAMICTAL

Recent Clinical Trials for LAMICTAL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brown UniversityPhase 2
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Phase 2
University of KarachiPhase 1

See all LAMICTAL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for LAMICTAL

US Patents and Regulatory Information for LAMICTAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-006 Jun 21, 2011 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-005 Apr 14, 2010 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Glaxosmithkline Llc LAMICTAL lamotrigine TABLET;ORAL 020241-005 Dec 27, 1994 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL ODT lamotrigine TABLET, ORALLY DISINTEGRATING;ORAL 022251-004 May 8, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Glaxosmithkline Llc LAMICTAL XR lamotrigine TABLET, EXTENDED RELEASE;ORAL 022115-003 May 29, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-004 Sep 8, 2000 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LAMICTAL

International Patents for LAMICTAL

See the table below for patents covering LAMICTAL around the world.

Country Patent Number Title Estimated Expiration
Austria 370097 See Plans and Pricing
Israel 60201 See Plans and Pricing
Japan S5625169 TRIAZINE DERIVATIVE See Plans and Pricing
Zimbabwe 12980 SUBSTITUTED AROMATIC COMPOUNDS See Plans and Pricing
Finland 67844 See Plans and Pricing
German Democratic Republic 151309 VERFAHREN ZUR HERSTELLUNG VON SUBSTITUIERTEN AMINOTRIAZINEN See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Medtronic
Colorcon
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.